Cancer Cell Patents (Class 424/155.1)
-
Patent number: 8173424Abstract: This invention provides novel erbB2-binding internalizing antibodies. The antibodies, designated F5 and C1, specifically bind to c-erbB2 antigen and, upon binding, are readily internalized into the cell bearing the c-erbB2 marker. Chimeric molecules comprising the F5 and/or C1 antibodies attached to one or more effector molecules are also provided.Type: GrantFiled: December 16, 2010Date of Patent: May 8, 2012Assignee: The Regents of the University of CaliforniaInventors: James D. Marks, Marie Alix Poul
-
Publication number: 20120107324Abstract: The invention relates to targeted binding agents against ?5?1 and uses of such agents. More specifically, the invention relates to fully human monoclonal antibodies directed to ?5?1. The described targeted binding agents are useful in the treatment of diseases associated with the activity and/or overproduction of ?5?1 and as diagnostics.Type: ApplicationFiled: December 21, 2009Publication date: May 3, 2012Inventors: Catherine Anne Eberlein, Ian Foltz, Jaspal Singh Kang, Jane Kendrew, Avril Alfred, Simon Thomas Barry
-
Patent number: 8163287Abstract: The invention relates to tumors expressing HER2 and EGFR, using HER2-dimerization inhibitors (HDIs) and EGFR inhibitors.Type: GrantFiled: July 19, 2006Date of Patent: April 24, 2012Assignee: Genentech, Inc.Inventors: Mark X. Sliwkowski, Stephen M. Kelsey
-
Publication number: 20120087915Abstract: Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.Type: ApplicationFiled: June 3, 2011Publication date: April 12, 2012Applicant: Pharmacyclics, Inc.Inventors: Joseph J. Buggy, Laurence Elias, Gwen Fyfe, Eric Hedrick, David J. Loury, Tarak D. Mody
-
Patent number: 8147831Abstract: The present invention provides humanized, chimeric and human anti-CD19 antibodies, anti-CD19 antibody fusion proteins, and fragments thereof that bind to a human B cell marker. Such antibodies, fusion proteins and fragments thereof are useful for the treatment and diagnosis of various B-cell disorders, including B-cell malignancies and autoimmune diseases. In more particular embodiments, the humanized anti-CD19 antibodies may comprise one or more framework region amino acid substitutions designed to improve protein stability, antibody binding and/or expression levels. In a particularly preferred embodiment, the substitutions comprise a Ser91Phe substitution in the hA19 VH sequence.Type: GrantFiled: October 19, 2010Date of Patent: April 3, 2012Assignee: Immunomedics, Inc.Inventors: Hans J. Hansen, Zhengxing Qu, David M. Goldenberg
-
Patent number: 8147832Abstract: A CD20-binding polypeptide composition comprising a combination of a modified heavy chain variable region polypeptide and a modified light chain variable region polypeptide. The combination can be (a) a modified 2B8 antibody heavy chain variable region polypeptide of SEQ ID NO: 48; and a modified 2B8 antibody light chain variable region polypeptide of SEQ ID NO: 49; or (b) a modified Leu16 antibody heavy chain variable region polypeptide of SEQ ID NO: 50; and a modified Leu16 antibody light chain variable region polypeptide of SEQ ID NO: 51.Type: GrantFiled: August 13, 2004Date of Patent: April 3, 2012Assignee: Merck Patent GmbHInventors: Francis Joseph Carr, Stephen Williams, Stephen D. Gillies
-
Publication number: 20120070442Abstract: Provided herein are methods for identifying a cancer patient responsive to treatment with an EGFR tyrosine kinase inhibitor. One method comprises obtaining a biopsy from the patient and measuring the number of copies of miR-128b in DNA extracted from the biopsy. A patient responsive to EGFR tyrosine kinase inhibitor treatment has a cancer with less than two copies of miR-128b DNA. Another method comprises measuring miR-128b or miR-128a level in a biopsy obtained from the patient and comparing that level to miR-128b or miR-128a level in a normal tissue sample. A patient responsive to treatment with an EGFR tyrosine kinase inhibitor has a cancer expressing a lower level of miR-128b or miR-128a relative to normal tissue. Further provided herein are methods for treating cancer in a patient in need thereof. One method comprises measuring the level of miR-128b or miR-128a in a biopsy obtained from the patient and administering to the patient an EGFR tyrosine kinase inhibitor.Type: ApplicationFiled: August 11, 2008Publication date: March 22, 2012Applicant: The Regents of the University of Colorado, a body corporateInventors: Glen Joel Weiss, Lynne Bemis, Paul A. Bunn, JR., Wilber A/ Franklin
-
Publication number: 20120070438Abstract: Methods of inhibiting melanoma tumor growth, methods of treating melanoma and metastatic melanoma, and methods of reducing the frequency of tumor initiating cells (or cancer stem cells) in melanoma tumors are described. The methods described comprise administering a DLL4 antagonist (e.g., an antibody that specifically binds the extracellular domain of human DLL4) to a subject. Related polypeptides and polynucleotides, compositions comprising the DLL4 antagonists, and methods of making the DLL4 antagonists are also described.Type: ApplicationFiled: September 9, 2011Publication date: March 22, 2012Applicant: OncoMed Pharmaceuticals, Inc.Inventors: Timothy C. Hoey, Lucia Beviglia
-
Patent number: 8129502Abstract: The present invention relates to a method for producing cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, and hematogenous cells.Type: GrantFiled: November 13, 2007Date of Patent: March 6, 2012Assignee: Hoffmann-La Roche Inc.Inventors: David S. F. Young, Helen P. Findlay, Susan E. Hahn, Lisa M. Cechetto
-
Patent number: 8124738Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to CD70 with high affinity. Nucleic acid molecules encoding the antibodies of the disclosure, expression vectors, host cells and methods for expressing the antibodies of the disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the disclosure are also provided. The disclosure also provides methods for treating cancer, autoimmune disease, inflammation and viral infections.Type: GrantFiled: September 26, 2006Date of Patent: February 28, 2012Assignee: Medarex, Inc.Inventors: Jonathan Alexander Terret, Li-sheng Lu, David John King, Josephine M. Cardarelli, Chin Pan, Haichun Huang, Marco A. Coccia
-
Patent number: 8119138Abstract: Compositions for treating cancers of mucosal tissues including breast, prostate, ovary, colon are disclosed which include various combinations of new or conventional anti-estrogen compounds, aromatase inhibitors, immune modulators, immune inhibitors, immune inhibitor mimicking compounds and steroid or thyroid hormones. Methods of predicting susceptibility of a cancer of mucosal origin to treatment with a composition containing an immune inhibitor or an immune inhibitor mimicking compound are also disclosed. Preferred methods include identifying in a specimen of cancer cells the presence of a Poly-Ig (Fc) receptor or Poly-Ig-like (Fc) receptor capable of binding to an immune inhibitor or an immune inhibitor mimicking compound and of mediating immune inhibition of cancer cell growth.Type: GrantFiled: November 13, 2002Date of Patent: February 21, 2012Assignee: Signe Biopharma Inc.Inventor: David A. Sirbasku
-
Publication number: 20120039984Abstract: A glycolipopeptide comprising a carbohydrate component, a peptide component and a lipid component, for use as a therapeutic or prophylactic vaccine. Also provided are monoclonal and polyclonal antibodies that recognize the glycolipopeptide of the invention, as well as uses thereof.Type: ApplicationFiled: July 2, 2009Publication date: February 16, 2012Applicant: University of Georgia Research Foundation, Inc.Inventors: Geert-Jan Boons, Therese Buskas, Alex J. Harvey, Sampat Ingale, Margaretha Wolfert, Robert Lance Wells
-
Patent number: 8114403Abstract: Cancer treatments use a therapy that: 1) interferes with the interaction between CD200 and its receptor to block immune suppression thereby promoting eradication of the cancer cells; and 2) directly kills the cancer cells either by complement-mediated or antibody-dependent cellular cytotoxicity or by targeting cells using a fusion molecule that includes a CD200-targeting portion. The therapy includes the administration of novel antibodies, functional fragments thereof or fusion molecules containing portions thereof.Type: GrantFiled: March 1, 2010Date of Patent: February 14, 2012Assignee: Alexion Pharmaceuticals, Inc.Inventors: Katherine S. Bowdish, John McWhirter, Anke Kretz-Rommel, Toshiaki Maruyama
-
Publication number: 20120034227Abstract: The present invention relates to the use of binding equivalents of monoclonal antibody 31.1, including chimerized and/or humanized versions thereof, antibody fragments as well as competitively binding and co-specific antibodies and antibody fragments, in the treatment of pancreatic cancer.Type: ApplicationFiled: January 21, 2011Publication date: February 9, 2012Applicant: NEOGENIX ONCOLOGY, INC.Inventors: Myron Arlen, Kwong Tsang
-
Patent number: 8110194Abstract: A disease or condition, such as cancer or an infectious disease, can be treated in a patient by administering a CTLA-4 antibody in an escalating dosage regimen until a partial or complete response is elicited in the patient or a pre-determined maximum dosage is reached.Type: GrantFiled: December 7, 2006Date of Patent: February 7, 2012Assignee: Medarex, Inc.Inventors: Geoffrey M. Nichol, Israel Lowy
-
Publication number: 20120027770Abstract: The invention relates to a novel cell derived from the human body, where said cell comprises a Clever-1 receptor; to a method for affecting the immune system of an individual and for treatment of diseases or conditions related to the function of the immune system and to methods for screening of cancer patients that may respond to an anti-Clever-1 therapy or for diagnosing of a pregnancy complication or for estimating the risk of such complication in a pregnant woman.Type: ApplicationFiled: April 6, 2010Publication date: February 2, 2012Applicant: FARON PHARMACEUTICALS OYInventors: Sirpa Jalkanen, Marko Salmi, Markku Jalkanen
-
Patent number: 8105596Abstract: B-cell malignancies, such as the B-cell subtype of non-Hodgkin's lymphoma and chronic lymphocytic leukemia, are significant contributors to cancer mortality. The response of B-cell malignancies to various forms of treatment is mixed. Traditional methods of treating B-cell malignancies, including chemotherapy and radiotherapy, have limited utility due to toxic side effects. Immunotherapy with anti-CD20 antibodies have also provided limited success. The use of antibodies that bind with the CD22 or CD19 antigen, however, provides an effective means to treat B-cell malignancies such as indolent and aggressive forms of B-cell lymphomas, and acute and chronic forms of lymphatic leukemias. Moreover, immunotherapy with anti-CD22 and/or anti-CD19 antibodies requires comparatively low doses of antibody protein, and can be used effectively in multimodal therapies.Type: GrantFiled: March 15, 2011Date of Patent: January 31, 2012Assignee: Immunomedics, Inc.Inventor: David M. Goldenberg
-
Publication number: 20120020880Abstract: This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of primary and metastatic human tumor cells; and most particularly to the use of an isolated monoclonal antibody or cancerous disease modifying antibodies (CDMAB) thereof, optionally in combination with one or more chemotherapeutic agents, as a means for initiating the cytotoxic response in such human tumors, e.g. any primary or metastatic tumor sites which arise from hepatocytes. The invention further relates to binding assays which utilize the CDMAB of the instant invention.Type: ApplicationFiled: September 23, 2011Publication date: January 26, 2012Applicant: HOFFMANN-LA ROCHE INC.Inventors: David S. F. Young, Daad Sayegh, Sheung Tat Fan, Ronnie Tung Ping Poon, Terence Kin Wah Lee
-
Patent number: 8101179Abstract: A murine anti-CD20 monoclonal antibody having cell growth inhibitory activities is disclosed. Cell growth inhibitory activities include apoptosis against human CD20 antigen expressing cells in culture of the CD20 antigen expressing cells without effector cells. The anti-CD20 monoclonal antibody is incorporated into chimeric anti-CD20 monoclonal antibodies in which the amino acid sequences of the variable regions of the anti-CD20 monoclonal antibody and the amino acid sequences of the constant regions of human immunoglobulin are fused. Also a humanized anti-CD20 monoclonal antibody is described which includes all of the variable region CDRs of the H chain of the anti-CD20 monoclonal antibody and all of the variable region CDRs of the L chain of the anti-CD20 monoclonal antibody and an amino acid sequence of human immunoglobulin. A nucleotide sequence encoding the amino acid sequence of the chimeric or humanized anti-CD20 monoclonal antibody can be expressed in mammalian cells.Type: GrantFiled: March 31, 2006Date of Patent: January 24, 2012Assignee: Biomedics Inc.Inventors: Masanori Numazaki, Tetsuo Nakamura, Sadakazu Usuda, Eduardo A. Padlan
-
Publication number: 20120014948Abstract: The invention relates to the identification of genetic products that are expressed in association with a tumor and the nucleic acid coding therefor. The invention relates to the therapy and diagnosis of diseases in which the genetic products that are expressed in association with a tumor are expressed in an aberrant manner. The invention also relates to proteins, polypeptides, and peptides which are expressed in association with a tumor and the nucleic acids coding therefor.Type: ApplicationFiled: July 18, 2011Publication date: January 19, 2012Inventors: Ugur Sahin, Özlem Türeci, Michael Koslowski
-
Patent number: 8097252Abstract: Methods and compositions are described for targeting therapeutic and diagnostic molecules to particular types of cells using targeting antibodies or other targeting moeities.Type: GrantFiled: January 6, 2011Date of Patent: January 17, 2012Assignee: Immunomedics, Inc.Inventors: William J. McBride, Chien-Hsing Chang, David M. Goldenberg, Hans J. Hansen
-
Patent number: 8097251Abstract: The present invention relates to functional heavy chain antibodies, functional single domain heavy chain antibodies, functional VH domains, or functional fragments thereof including an amino acid which is neither a charged amino acid nor a C at position 45, and including an amino acid at position 103 independently chosen from the group consisting of R, G, K, S, Q, L, and P, and optionally an amino acid at position 108 independently chosen from the group consisting of Q, L and R, the positions determined according to the Kabat numbering.Type: GrantFiled: June 23, 2006Date of Patent: January 17, 2012Assignee: Vlaams Interuniversitair Instituut Voor Biotechnologie VZWInventors: Serge Muyldermans, Karen Silence
-
Patent number: 8088383Abstract: Methods of therapy for B-cell malignancies are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment thereof to a patient in need thereof. The antagonist anti-CD40 antibody or antigen-binding fragment thereof is free of significant agonist activity when the antibody binds a CD40 antigen on a normal human B cell, exhibits antagonist activity when the antibody binds a CD40 antigen on a malignant human B cell, and can exhibit antagonist activity when the antibody binds a CD40 antigen on a normal human B cell. Antagonist activity of the anti-CD40 antibody or antigen-binding fragment thereof beneficially inhibits proliferation and/or differentiation of malignant human B cells.Type: GrantFiled: September 27, 2010Date of Patent: January 3, 2012Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: Keting Chu, Lorianne K. Masuoka
-
Patent number: 8088378Abstract: The present invention is directed to anti-CD79b antibody, huMA79b.v28, and compositions of matter thereof useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.Type: GrantFiled: July 15, 2008Date of Patent: January 3, 2012Assignee: Genetech Inc.Inventors: Yvonne Chen, Mark Dennis, David Dornan, Kristi Elkins, Jagath Reddy Junutula, Andrew Polson, Bing Zheng
-
Patent number: 8088377Abstract: Isolated human monoclonal antibodies which bind to CD30 (e.g., human CD30) are disclosed. The human antibodies can be produced in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are derivatives of the human antibodies (e.g., bispecific antibodies and immunoconjugates), pharmaceutical compositions comprising the human antibodies, non-human transgenic animals and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.Type: GrantFiled: April 4, 2008Date of Patent: January 3, 2012Assignee: Medarex, Inc.Inventors: Tibor Keler, Robert Graziano, John Treml, Yashwant M. Deo
-
Patent number: 8088357Abstract: The invention relates to recognition molecules which are directed towards tumors and can be used in the diagnosis and therapy of tumor diseases.Type: GrantFiled: December 1, 2003Date of Patent: January 3, 2012Assignee: Nemod Biotherapeutics GmbH & Co. KGInventors: Steffen Goletz, Antje Danielczyk, Uwe Karsten, Peter Ravn, Renate Stahn, Peter Astrup Christensen
-
Patent number: 8075892Abstract: The present invention concerns the treatment of disorders characterized by the overexpression of ErbB2. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer overexpressing ErbB2 with a combination of an anti-ErbB2 antibody and a chemotherapeutic agent other than an anthracycline, e.g. doxorubicin or epirubicin. The invention further provides a method of treating cancer in a human patient comprising administering effective amounts of an anti-ErbB2 antibody and a cardioprotectant to the patient.Type: GrantFiled: July 20, 2007Date of Patent: December 13, 2011Assignee: Genentech, Inc.Inventor: Susan D. Hellmann
-
Publication number: 20110300131Abstract: The application provides methods of diagnosis, prognosis, prophylaxis and treatment of ovarian, pancreatic and other cancers using antibodies that specifically bind to denatured CD70.Type: ApplicationFiled: April 10, 2009Publication date: December 8, 2011Applicant: SEATTLE GENETICS, INC.Inventors: Maureen Ryan, Maria Leia Smith
-
Patent number: 8071072Abstract: This invention relates to the staging, diagnosis and treatment of cancerous diseases (both primary tumors and tumor metastases), particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more CDMAB/chemotherapeutic agents, as a means for initiating the cytotoxic response. The invention further relates to binding assays, which utilize the CDMAB of the instant invention. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, cytokines, interferons, target or reporter moieties and hematogenous cells.Type: GrantFiled: May 30, 2007Date of Patent: December 6, 2011Assignee: Hoffmann-La Roche Inc.Inventors: David S. F. Young, Helen P. Findlay, Susan E. Hahn, Lisa M. Cechetto, Fortunata McConkey, Maximiliano Vasquez
-
Patent number: 8067000Abstract: The present invention relates to therapeutic protocols and pharmaceutical compositions designed to treat and prevent cancer. More specifically, the present invention relates to a novel method of treating cancer using antagonists to the endothelin B receptor (ETB) or inactive mimic forms of endothelin-1. The pharmaceutical compositions of the invention are capable of selectively inhibiting the early events associated with the development of cancer. The present invention further relates to screening assays to identify compounds which inhibit ETB activation.Type: GrantFiled: May 22, 2009Date of Patent: November 29, 2011Assignee: New York UniversityInventors: Robert J. Schneider, Sumayah Jamal
-
Publication number: 20110287021Abstract: The present invention features polypeptides, such as antibodies, and their use in the treatment and diagnosis of neoplasms.Type: ApplicationFiled: May 19, 2011Publication date: November 24, 2011Applicant: PATRYS LIMITEDInventors: Hans-Konrad Mueller-Hermelink, Heinz Peter Vollmers
-
Publication number: 20110287020Abstract: This disclosure provides modified cytosine deaminases (CDs). The disclosure further relates to cells and vector expressing or comprising such modified CDs and methods of using such modified CDs in the treatment of disease and disorders.Type: ApplicationFiled: March 26, 2011Publication date: November 24, 2011Applicant: TOCAGEN INC.Inventors: Harry E. Gruber, Douglas J. Jolly, Omar D. Perez, Christopher R. Logg
-
Patent number: 8063187Abstract: The present invention relates to immunoglobulins that bind Fc?RIIb+ cells and coengage the antigen on the cell's surface and an Fc?RIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins.Type: GrantFiled: May 30, 2008Date of Patent: November 22, 2011Assignee: Xencor, Inc.Inventors: Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Gregory L. Moore, Igor Vostiar
-
Publication number: 20110256124Abstract: The invention provides a method for increasing the bioactivity (e.g. the biosafety and efficacy) of a therapeutic IgE antibody of the invention in the treatment of a patient. Methods of the invention include: i) administering to the patient a therapeutic IgE antibody in combination with at least one bioactivity-enhancing agent, ii) strategic treatment regimens and protocols for the dosing and administration of a therapeutic IgE antibody of the invention, and iii) the use of a therapeutic IgE antibody having a variable region comprising at least one antigen binding region specific for binding an epitope of an antigen wherein the epitope is not highly repetitive or is non-repetitive.Type: ApplicationFiled: October 7, 2010Publication date: October 20, 2011Inventors: Birgit C. Schultes, Christopher F. Nicodemus
-
Publication number: 20110256147Abstract: Methods of diagnosis and treatment of malignant tumors, in particular ovarian tumors, using GD3 and GD3 inhibitors. Also provided are methods of modulating the immune system of a mammal by the administration of a GD3 and GD3 inhibitors.Type: ApplicationFiled: December 1, 2009Publication date: October 20, 2011Applicant: THE JOHNS HOPKINS UNIVERSITYInventors: Mathias Oelke, Jonathan Schneck, Tonya Webb
-
Patent number: 8039595Abstract: The present invention relates to a cell for the production of an antibody molecule such as an antibody useful for various diseases having high antibody-dependent cell-mediated cytotoxic activity, a fragment of the antibody and a fusion protein having the Fc region of the antibody or the like, a method for producing an antibody composition using the cell, the antibody composition and use thereof.Type: GrantFiled: January 9, 2009Date of Patent: October 18, 2011Assignee: Kyowa Hakko Kirin Co., Ltd.Inventors: Yutaka Kanda, Mitsuo Satoh, Kazuyasu Nakamura, Kazuhisa Uchida, Toyohide Shinkawa, Naoko Yamane, Emi Hosaka, Kazuya Yamano, Motoo Yamasaki, Nobuo Hanai
-
Patent number: 8038999Abstract: A method of treating breast cancer that is at least partially ER+ is disclosed. The method comprises administering at a tumor site in a mammalian subject a pharmaceutically acceptable form of Fe(II) or Fe(III) in a suitable carrier. A four-part program aimed at eradicating breast cancer includes (a) local treatment and prevention of spread from a contained breast site, preferably using local administration of a ferric iron composition, (b) treatment of disseminated (metastatic) breast cancer, (c) reduction in the risk of developing breast cancer, preferably by enhancing dimeric/polymeric IgA and polymeric IgM inhibition of estrogen responsive cell growth, and (d) protection against cancer causing agents.Type: GrantFiled: November 28, 2007Date of Patent: October 18, 2011Inventor: David A. Sirbasku
-
Patent number: 8038996Abstract: Anti-CEACAM6 antibodies and antibody fragments, nucleic acids encoding them, methods of their manufacture, and methods to treat cancer using these compounds are provided.Type: GrantFiled: March 10, 2005Date of Patent: October 18, 2011Assignee: University of ArizonaInventor: Daruka Mahadevan
-
Patent number: 8038998Abstract: Improved methods for treatment of cancer which involve the targeting of slow-growing, relatively mutationally-spared cancer stem line are provided. These methods are an improvement over previous cancer therapeutic methods because they provide for very early cancer treatment and reduce the likelihood of clinical relapse after treatment.Type: GrantFiled: November 10, 2005Date of Patent: October 18, 2011Inventor: Ivan Bergstein
-
Publication number: 20110250201Abstract: The present invention is directed to therapeutic methods using IL-6 antagonists such as antibodies and fragments thereof having binding specificity for IL-6 to improve survivability or quality of life of a patient in need thereof. In preferred embodiments, the anti-IL-6 antibodies will be humanized and/or will be aglycosylated. Also, in preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level or a reduced serum albumin level prior to treatment. In another preferred embodiment, the patient's Glasgow Prognostic Score will be increased and survivability will preferably be improved.Type: ApplicationFiled: November 24, 2009Publication date: October 13, 2011Inventor: Jeffrey T.L. SMITH
-
Publication number: 20110250166Abstract: The present invention relates to a combined preparation comprising at least one rocaglamide derivative and at least one apoptosis inducing agent, preferably from the group of substances comprising agents inducing the extrinsic apoptotic pathway, antiproliferative agents and agents which induce apoptosis in T-cells by activation induced cell death (AICD) for the treatment of cancer.Type: ApplicationFiled: November 20, 2009Publication date: October 13, 2011Applicant: DKFZ DEUTSCHES KREBSFORSCHUNGSZENTRUMInventors: Min Li-Weber, Peter H. Krammer
-
Patent number: 8034904Abstract: Antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of these molecules with cytotoxic agents, which specifically bind to and inhibit insulin-like growth factor-I receptor, antagonize the effects of IGF-I and are substantially devoid of agonist activity toward the insulin-like growth factor-I receptor. These molecules can be conjugated to cytotoxic agents for use in the treatment of tumors that express elevated levels of IGF-I receptor, such as breast cancer, colon cancer, lung cancer, ovarian carcinoma, synovial sarcoma and pancreatic cancer. These molecules can also be labeled for in vitro and in vivo diagnostic uses, such as in the diagnosis and imaging of tumors that express elevated levels of IGF-I receptor.Type: GrantFiled: December 8, 2003Date of Patent: October 11, 2011Assignee: Immunogen Inc.Inventors: Rajeeva Singh, Daniel J. Tavares, Nancy E. Dagdigian
-
Patent number: 8034352Abstract: The present invention concerns methods and compositions for forming cytokine-antibody complexes using dock-and-lock technology. In preferred embodiments, the cytokine-MAb DNL complex comprises an IgG antibody attached to two AD (anchor domain) moieties and four cytokines, each attached to a DDD (docking and dimerization domain) moiety. The DDD moieties form dimers that bind to the AD moieties, resulting in a 2:1 ratio of DDD to AD. The cytokine-MAb complex exhibits improved pharmacokinetics, with a significantly longer serum half-life than either naked cytokine or PEGylated cytokine. The cytokine-MAb complex also exhibits significantly improved in vitro and in vivo efficacy compared to cytokine alone, antibody alone, unconjugated cytokine plus antibody or cytokine-MAb DNL complexes incorporating an irrelevant antibody. In more preferred embodiment the cytokine is G-CSF, erythropoietin or INF-?2b.Type: GrantFiled: April 1, 2010Date of Patent: October 11, 2011Assignee: IBC Pharmaceuticals, Inc.Inventors: Chien-Hsing Chang, David M. Goldenberg, Edmund A. Rossi
-
Publication number: 20110236393Abstract: The presently disclosed subject matter provides methods of inhibiting a host innate response to activator-mediated proliferative signals in a primary B cell. In some embodiments a method is provided for immortalized primary B cells. In some embodiments a method is provided for increasing efficiency of EBV transformation of primary B cells. In some embodiments a method is provided for increasing proliferation of primary B cells in culture. In some embodiments a method is provided for producing a monoclonal antibody. In some embodiments a method is provided for identifying a novel broadly neutralizing antibody having a desired antigen specificity. Also provided are antibodies produced according the methods of the presently disclosed subject matter.Type: ApplicationFiled: November 4, 2009Publication date: September 29, 2011Inventors: Kwan-ki Hwang, Micah Luftig
-
Patent number: 8025883Abstract: The invention describes methods for inhibiting angiogenesis in a tissue by administering an antagonist that specifically binds to a proteolyzed or denatured collagen but not to native triple helical forms of the collagen. Antagonists of the invention can target, for example, denatured collagens type-I, type-II, type-III, type-IV, type-V and combinations thereof. Methods utilizing such antagonists for therapeutic treatment of tumor growth, tumor metastasis or of restenosis also are described, as are methods to use such antagonists as diagnostic markers of angiogenesis is normal or diseased tissues both in vivo and ex vivo. Antagonists include monoclonal antibodies referred to as HUI77, HUIV26, and XL313.Type: GrantFiled: September 15, 2005Date of Patent: September 27, 2011Assignee: University of Southern CaliforniaInventors: Peter C. Brooks, Jingsong Xu, Eric Petitclerc
-
Publication number: 20110229552Abstract: The present invention relates to novel nucleic acid and protein molecules and their use in cancer therapy and diagnosis.Type: ApplicationFiled: January 23, 2007Publication date: September 22, 2011Inventors: Erno Vreugdenhil, Petru Van Kuik-Romeijn, Gerard Johannes Platenburg
-
Patent number: 8013128Abstract: Antibodies and molecules derived therefrom that bind to novel PSCA protein, and variants thereof, are described wherein PSCA exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, PSCA provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The PSCA gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with PSCA can be used in active or passive immunization.Type: GrantFiled: March 4, 2009Date of Patent: September 6, 2011Assignee: Agensys, Inc.Inventors: Jean Gudas, Aya Jakobovits, Xiao-chi Jia, Robert Kendall Morrison, Karen Jane Meyrick Morrison, Hui Shao, Pia M. Challita-Eid, Arthur B. Raitano
-
Patent number: 8012470Abstract: According to the invention there is described a method for ex vivo immunization of humans and animals comprising the following steps of: a) isolating autologous tumor cells; b) treating the tumor cells to prevent the survival thereof following reinfusion; c) incubating the thus treated tumor cells with intact heterologous bispecific and/or trisepcific antibodies showing the following properties: ?—binding to a T cell; ?—binding to at least one antigen on a tumor cell; ?—binding, by their Fc portion (in the case of bispecific antibodies), or by a third specificity (in the case of trispecific antibodies) to Fc receptor-positive cells.Type: GrantFiled: July 20, 2005Date of Patent: September 6, 2011Assignee: Helmholtz Zentrum Munchen Deutsches Forschungszentrum fur Gesundheit und Umwelt (GmbH)Inventors: Horst Lindhofer, Hans-Joachim Kolb, Reinhard Zeidler, Georg Bornkamm
-
Patent number: 8007797Abstract: The present invention relates to the use of a compound that specifically binds to JAM-C or JAM-B for the treatment of gliomas. More specifically the invention relates to the use of an antagonist of JAM-B or JAM-C for the treatment of glioma, in particular astrocytoma.Type: GrantFiled: September 28, 2007Date of Patent: August 30, 2011Assignee: Merck Serono S.A.Inventors: Pierre-Yves Dietrich, Mirna Tenan, Michel Aurrand-Lions, Beat Albert Imhof
-
Patent number: 8007799Abstract: The present invention provides vascular endothelial cell growth factor (VEGF) antagonists and methods of using VEGF antagonists. VEGF antagonists contemplated by the invention include VEGF antibodies and VEGF receptor fusion proteins. Methods of treating edema and stroke using VEGF antagonists are also provided.Type: GrantFiled: September 29, 2006Date of Patent: August 30, 2011Assignee: Genentech, Inc.Inventors: Nicholas Van Bruggen, Napoleone Ferrara